Biogen News and Research

RSS
New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

New ebook provides essential insights into Pharma compliance

New ebook provides essential insights into Pharma compliance

Now, hospitals can safely contain HCAI with Howorth Air Technology's BioSphere

Now, hospitals can safely contain HCAI with Howorth Air Technology's BioSphere

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

RBCC's injectable technology poised to improve use of addiction treatment drug

RBCC's injectable technology poised to improve use of addiction treatment drug

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

RBCC’s BiO Assay wins grant from CASIS for Biological Research in Microgravity

RBCC’s BiO Assay wins grant from CASIS for Biological Research in Microgravity

TPP wins $500,000 grant from Biogen Idec to help students start and run own businesses

TPP wins $500,000 grant from Biogen Idec to help students start and run own businesses

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Scientists receive grant from Biogen Idec to study everyday activities in MS using actual reality

Scientists receive grant from Biogen Idec to study everyday activities in MS using actual reality

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Whitehead Institute enters into scientific research collaboration with Biogen Idec

Whitehead Institute enters into scientific research collaboration with Biogen Idec

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients